Immunovant, Roivant slip after trial data for autoimmune disorder therapy
Immunovant's (NASDAQ:IMVT) stock and Roivant Sciences (ROIV) stock fall after trial data for the former's autoimmune disease ...
STAT9d
Immunovant and Roivant report success in autoimmune drug’s Phase 3 trial
The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.
Roivant says Immunovant announces results from Phase 3 study of batoclimab in MG
Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...
Fierce Biotech8d
Immunovant won't seek approval for autoimmune drug despite phase 3 win
Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...
Benzinga.com9d
STAT+: Immunovant and Roivant report success in autoimmune drug's Phase 3 trial
An antibody treatment from Immunovant and Roivant Sciences significantly reduced symptoms and disease activity in patients with generalized myasthenia gravis, a debilitating autoimmune disease ...
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data
Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...
Investor's Business Daily on MSN8d
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.
Nasdaq9d
Immunovant, Inc. to Host Investor Webcast on Phase 3 Study Results for Batoclimab in MG and Phase 2b Study in CIDP
The session will feature Pete Salzmann, CEO of Immunovant, alongside Matt Gline, CEO of Roivant. The live webcast can be accessed through the Roivant Investors website and will be available for ...